EMEA-001493-PIP03-18
Key facts
Invented name |
Xalkori
|
Active substance |
crizotinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0399/2019
|
PIP number |
EMEA-001493-PIP03-18
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|